TARSUS PHARMACEUTICALS, INC. Basic Shares Outstanding (Weighted Average)
TARSUS PHARMACEUTICALS, INC. (TARS) reported Basic Shares Outstanding (Weighted Average) of 43.39 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 43.39M shares, a 2.44% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 42.96M shares, a 9.18% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 42.76M shares, a 10.91% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 42.61M shares, a 11.01% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2025 was 41.78M shares, a 11.11% increase from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2024 was 37.60M shares, a 27.98% increase from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2023 was 29.38M shares, a 19.35% increase from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic for fiscal 2022 was 24.62M shares, a 19.78% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 43.39M shares 10-Q · filed 2026-08-06 | 43.18M shares 10-Q · filed 2026-08-06 | 43.04M shares derived: average of 3 quarters · filed 2026-08-06 | 42.93M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 42.96M shares 10-Q · filed 2026-05-06 | 42.86M shares derived: average of 2 quarters · filed 2026-05-06 | 42.78M shares derived: average of 3 quarters · filed 2026-05-06 | 42.67M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 42.76M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | 42.69M shares derived: average of 2 quarters · filed 2026-02-23 | 42.58M shares derived: average of 3 quarters · filed 2026-08-06 | 41.78M shares 10-K · filed 2026-02-23 |
| 2025-09-30 | 42.61M shares 10-Q · filed 2025-11-04 | 42.48M shares derived: average of 2 quarters · filed 2026-08-06 | 41.46M shares 10-Q · filed 2025-11-04 | 40.72M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 42.36M shares 10-Q · filed 2026-08-06 | 40.87M shares 10-Q · filed 2026-08-06 | 40.09M shares derived: average of 3 quarters · filed 2026-08-06 | 39.66M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 39.35M shares 10-Q · filed 2026-05-06 | 38.95M shares derived: average of 2 quarters · filed 2026-05-06 | 38.76M shares derived: average of 3 quarters · filed 2026-05-06 | 38.53M shares derived: average of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | 38.56M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | 38.47M shares derived: average of 2 quarters · filed 2026-02-23 | 38.25M shares derived: average of 3 quarters · filed 2026-02-23 | 37.60M shares 10-K · filed 2026-02-23 |
| 2024-09-30 | 38.38M shares 10-Q · filed 2025-11-04 | 38.10M shares derived: average of 2 quarters · filed 2025-11-04 | 37.29M shares 10-Q · filed 2025-11-04 | 36.21M shares derived: average of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | 37.82M shares 10-Q · filed 2025-08-06 | 36.53M shares 10-Q · filed 2025-08-06 | 35.49M shares derived: average of 3 quarters · filed 2026-02-23 | 34.27M shares derived: average of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | 35.30M shares 10-Q · filed 2025-05-01 | 34.32M shares derived: average of 2 quarters · filed 2026-02-23 | 33.09M shares derived: average of 3 quarters · filed 2026-02-23 | 31.52M shares derived: average of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | 33.34M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | 31.98M shares derived: average of 2 quarters · filed 2026-02-23 | 30.26M shares derived: average of 3 quarters · filed 2026-02-23 | 29.38M shares 10-K · filed 2026-02-23 |
| 2023-09-30 | 30.62M shares 10-Q · filed 2024-11-13 | 28.72M shares derived: average of 2 quarters · filed 2024-11-13 | 28.07M shares 10-Q · filed 2024-11-13 | 27.72M shares derived: average of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | 26.82M shares 10-Q · filed 2024-08-08 | 26.78M shares 10-Q · filed 2024-08-08 | 26.76M shares derived: average of 3 quarters · filed 2025-02-25 | 26.73M shares derived: average of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | 26.74M shares 10-Q · filed 2024-05-08 | 26.73M shares derived: average of 2 quarters · filed 2025-02-25 | 26.70M shares derived: average of 3 quarters · filed 2025-02-25 | 26.11M shares derived: average of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | 26.71M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | 26.69M shares derived: average of 2 quarters · filed 2025-02-25 | 25.90M shares derived: average of 3 quarters · filed 2025-02-25 | 24.62M shares 10-K · filed 2025-02-25 |
| 2022-09-30 | 26.66M shares 10-Q · filed 2023-11-09 | 25.50M shares derived: average of 2 quarters · filed 2023-11-09 | 23.92M shares 10-Q · filed 2023-11-09 | 23.10M shares derived: average of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | 24.33M shares 10-Q · filed 2023-08-10 | 22.53M shares 10-Q · filed 2023-08-10 | 21.91M shares derived: average of 3 quarters · filed 2023-08-10 | 21.59M shares derived: average of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | 20.71M shares 10-Q · filed 2023-05-09 | 20.70M shares derived: average of 2 quarters · filed 2023-05-09 | 20.68M shares derived: average of 3 quarters · filed 2023-05-09 | 20.65M shares derived: average of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | 20.68M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | 20.66M shares derived: average of 2 quarters · filed 2023-03-17 | 20.63M shares derived: average of 3 quarters · filed 2023-03-17 | 20.55M shares 10-K · filed 2023-03-17 |
| 2021-09-30 | 20.64M shares 10-Q · filed 2022-11-09 | 20.60M shares derived: average of 2 quarters · filed 2022-11-09 | 20.51M shares 10-Q · filed 2022-11-09 | 19.58M shares derived: average of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | 20.56M shares 10-Q · filed 2022-08-11 | 20.45M shares 10-Q · filed 2022-08-11 | 19.23M shares derived: average of 3 quarters · filed 2022-08-11 | 15.10M shares derived: average of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | 20.34M shares 10-Q · filed 2022-05-11 | 18.57M shares derived: average of 2 quarters · filed 2022-05-11 | 13.29M shares derived: average of 3 quarters · filed 2022-05-11 | 10.63M shares derived: average of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | 16.80M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | 9.76M shares derived: average of 2 quarters · filed 2022-03-14 | 7.39M shares derived: average of 3 quarters · filed 2022-03-14 | 6.21M shares 10-K · filed 2022-03-14 |
| 2020-09-30 | 2.73M shares 10-Q · filed 2021-11-10 | 2.69M shares derived: average of 2 quarters · filed 2021-11-10 | 2.68M shares 10-Q · filed 2021-11-10 | |
| 2020-06-30 | 2.65M shares 10-Q · filed 2021-08-05 | 2.65M shares 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | 2.65M shares 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |